Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease

Research output: Contribution to journalArticle

1 Citation (Scopus)
93 Downloads (Pure)

Abstract

Pulmonary arterial hypertension (PAH) occurs in approximately 15 % of patients with systemic sclerosis (SSc). Annual screening with pulmonary function tests (PFT) is recommended to help identify those patients at risk of PAH. We have noted that patients with SSc who carry anti-centromere autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical evidence of PAH. To evaluate this further, we undertook a retrospective case-control study evaluating PFT results in patients with SSc in whom pulmonary complications have neither been diagnosed nor suspected. Patients were divided according to ACA carriage and groups compared for PFT results. The median forced vital capacity (FVC) was higher in ACA-positive patients (106 vs. 93 %, p = 0.004). The gas transfer factor (TLco) was significantly lower in the ACA group (62.5 vs. 71 %, p = 0.013). The resulting FVC:TLco was significantly higher for ACA-positive vs. ACA-negative patients with SSc (1.70 vs. 1.29,p <0.001). Our findings suggest patients carrying ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. The long-term sequelae of PFT abnormalities in those patients with ACA who do not subsequently develop PAH are unknown.

Original languageEnglish
Pages (from-to)869-871
JournalClinical Rheumatology
Volume33
Issue number6
Early online date22 Apr 2014
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Centromere
Systemic Scleroderma
Respiratory Function Tests
Lung Diseases
Anti-Idiotypic Antibodies
Autoantibodies
Pulmonary Hypertension
Vital Capacity
Transfer Factor
Lung
Vascular Resistance
Case-Control Studies
Gases

Cite this

@article{9d982b72738c4e4f9dc9229009e7e3a4,
title = "Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease",
abstract = "Pulmonary arterial hypertension (PAH) occurs in approximately 15 {\%} of patients with systemic sclerosis (SSc). Annual screening with pulmonary function tests (PFT) is recommended to help identify those patients at risk of PAH. We have noted that patients with SSc who carry anti-centromere autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical evidence of PAH. To evaluate this further, we undertook a retrospective case-control study evaluating PFT results in patients with SSc in whom pulmonary complications have neither been diagnosed nor suspected. Patients were divided according to ACA carriage and groups compared for PFT results. The median forced vital capacity (FVC) was higher in ACA-positive patients (106 vs. 93 {\%}, p = 0.004). The gas transfer factor (TLco) was significantly lower in the ACA group (62.5 vs. 71 {\%}, p = 0.013). The resulting FVC:TLco was significantly higher for ACA-positive vs. ACA-negative patients with SSc (1.70 vs. 1.29,p <0.001). Our findings suggest patients carrying ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. The long-term sequelae of PFT abnormalities in those patients with ACA who do not subsequently develop PAH are unknown.",
author = "J. Gunn and J.D. Pauling and N.J. McHugh",
year = "2014",
month = "6",
doi = "10.1007/s10067-014-2616-0",
language = "English",
volume = "33",
pages = "869--871",
journal = "Clinical Rheumatology",
issn = "1434-9949",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease

AU - Gunn, J.

AU - Pauling, J.D.

AU - McHugh, N.J.

PY - 2014/6

Y1 - 2014/6

N2 - Pulmonary arterial hypertension (PAH) occurs in approximately 15 % of patients with systemic sclerosis (SSc). Annual screening with pulmonary function tests (PFT) is recommended to help identify those patients at risk of PAH. We have noted that patients with SSc who carry anti-centromere autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical evidence of PAH. To evaluate this further, we undertook a retrospective case-control study evaluating PFT results in patients with SSc in whom pulmonary complications have neither been diagnosed nor suspected. Patients were divided according to ACA carriage and groups compared for PFT results. The median forced vital capacity (FVC) was higher in ACA-positive patients (106 vs. 93 %, p = 0.004). The gas transfer factor (TLco) was significantly lower in the ACA group (62.5 vs. 71 %, p = 0.013). The resulting FVC:TLco was significantly higher for ACA-positive vs. ACA-negative patients with SSc (1.70 vs. 1.29,p <0.001). Our findings suggest patients carrying ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. The long-term sequelae of PFT abnormalities in those patients with ACA who do not subsequently develop PAH are unknown.

AB - Pulmonary arterial hypertension (PAH) occurs in approximately 15 % of patients with systemic sclerosis (SSc). Annual screening with pulmonary function tests (PFT) is recommended to help identify those patients at risk of PAH. We have noted that patients with SSc who carry anti-centromere autoantibodies (ACA) often have PFT abnormalities, in the absence of clinical evidence of PAH. To evaluate this further, we undertook a retrospective case-control study evaluating PFT results in patients with SSc in whom pulmonary complications have neither been diagnosed nor suspected. Patients were divided according to ACA carriage and groups compared for PFT results. The median forced vital capacity (FVC) was higher in ACA-positive patients (106 vs. 93 %, p = 0.004). The gas transfer factor (TLco) was significantly lower in the ACA group (62.5 vs. 71 %, p = 0.013). The resulting FVC:TLco was significantly higher for ACA-positive vs. ACA-negative patients with SSc (1.70 vs. 1.29,p <0.001). Our findings suggest patients carrying ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. The long-term sequelae of PFT abnormalities in those patients with ACA who do not subsequently develop PAH are unknown.

UR - http://www.scopus.com/inward/record.url?scp=84901580102&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1007/s10067-014-2616-0

U2 - 10.1007/s10067-014-2616-0

DO - 10.1007/s10067-014-2616-0

M3 - Article

VL - 33

SP - 869

EP - 871

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 1434-9949

IS - 6

ER -